A5040737678- Prostate Cancer Treatment and Research
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Cancer, Lipids, and Metabolism
- PARP inhibition in cancer therapy
- Circular RNAs in diseases
- Statistical Methods in Clinical Trials
- Cancer-related molecular mechanisms research
- Renal cell carcinoma treatment
- Cyclone Separators and Fluid Dynamics
- Radiomics and Machine Learning in Medical Imaging
- MicroRNA in disease regulation
- Aerosol Filtration and Electrostatic Precipitation
- Ferroptosis and cancer prognosis
- interferon and immune responses
- Sirtuins and Resveratrol in Medicine
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Acute Myocardial Infarction Research
- Icing and De-icing Technologies
- Cardiovascular Health and Risk Factors
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
Shanghai Tenth People's Hospital
2023-2025
Tongji University
2023-2025
Bengbu Medical College
2020-2022
First Affiliated Hospital of Bengbu Medical College
2021
Weatherford College
2021
197 Background: Our previous research confirmed that for metastatic castration-resistant prostate cancer (mCRPC) patients with DNA damage repair (DDR) deficiency who have developed resistance to prior abiraterone, the combination of olaparib and abiraterone improves survival compared monotherapy. However, further is needed identify subgroups may benefit from alone or in pinpoint risk factors significantly associated poor prognosis these patients. This study aims explore value androgen...
Objective Prostate cancer (PCa) is a malignant neoplasm of the urinary system. This study aimed to use bioinformatics screen for core genes and biological pathways related PCa. Methods The GSE5957 gene expression profiles were obtained from Gene Expression Omnibus (GEO) database identify differentially expressed (DEGs). ontology (GO) Kyoto Encyclopedia Genes Genomes (KEGG) pathway enrichment analyses DEGs constructed by R language. Furthermore, protein–protein interaction (PPI) networks...
Sequencing of circulating tumor DNA (ctDNA) is a minimally invasive approach to reveal the genomic alterations cancer; however, its comparison with sequencing tissue has not been well documented in real-world patients aggressive-variant prostate cancer (AVPC). Concordance was assessed between progressive and matched ctDNA by next-generation for 63 AVPC. Associations progression-free survival (PFS) overall (OS) were investigated using Kaplan-Meier Cox regression analyses. A total 161 somatic...
Long non-coding RNAs (lncRNAs) have become potential therapeutic targets or promising prognostic biomarkers in cancers. However, individual gene does not show sufficient value for clear cell renal carcinoma (ccRCC). Therefore, this study aims to develop a combined lncRNA signature the prognosis of ccRCC.The transcriptome profiling data confirmed ccRCC cases were obtained from The Cancer Genome Atlas (TCGA; https://portal.gdc.cancer.gov/). significance, survival time and diagnostic...
To explore the influencing factors of prostate cancer occurrence, set up risk prediction model, require reference for preliminary diagnosis clinical doctors, this model searched database through data patients and hyperplasia National Clinical Medical Science Data Center.With help Stata SE 12.0 SPSS 25.0 software, biases between groups were balanced by propensity score matching. Based on matched data, relevant further screened stepwise logistic regression analysis, key variable artificial...
Background Upper tract urothelial carcinoma (UTUC) is a rare malignancy. The management of metastatic or unresectable UTUC mainly based on evidence extrapolated from histologically homologous bladder cancer, including platinum-based chemotherapy and immune checkpoint inhibitor alone, whereas exhibits more invasiveness, worse prognosis, comparatively inferior response to treatments. First-line immunochemotherapy regimens have been attempted in clinical trials for unselected naïve-treated...
<div>Abstract<p>Sequencing of circulating tumor DNA (ctDNA) is a minimally invasive approach to reveal the genomic alterations cancer; however, its comparison with sequencing tissue has not been well documented in real-world patients aggressive-variant prostate cancer (AVPC). Concordance was assessed between progressive and matched ctDNA by next-generation for 63 AVPC. Associations progression-free survival (PFS) overall (OS) were investigated using Kaplan–Meier Cox regression...
<p>Comparing Survival Outcomes in AVPC Subgroups: Additional Platinum-Based Chemo vs. Docetaxel-Only. outcomes of PFS (A) and OS (B) for additional Platinum-based chemotherapy or Docetaxel only the subgroups without any alteration involving tumor suppressor genes TP53, RB1, PTEN. (C) (D) with low concentration ctDNA (ctDNA% < 13.5%).</p>
<p>Comparison between STPH cohort of patients with AVPC and from Aparicio et al Corn studies. (A) Clinical characteristics. (B) Genomic alterations involving the tumor suppressor genes TP53, RB1 or PTEN.</p>
<p>Patients with AVPC demonstrate improved survival outcomes during Chemo compared NHT. PFS (<b>A</b>) and OS (<b>B</b>) of patients stratified NHT or Chemo.</p>
<p>AVPC patient survival outcomes with additional platinum-based chemotherapy or docetaxel only based on <i>TP53/RB1/PTEN</i> alterations and high ctDNA%. PFS (<b>A</b>) OS (<b>B</b>) of patients AVPC who underwent only, (<b>C</b>) (<b>D</b>) stratified (<b>E</b>) (<b>F</b>) ctDNA% (≥13.5%) only.</p>
<p>Clinical Characteristics of Patients with AVPC</p>
<p>Study design and integrative landscape of SMs, CNVs, deleterious GMs in patients with AVPC. <b>A,</b> Flow diagram according to treatment history. Tumor tissue matched ctDNA from 63 clinically defined All them underwent systemic treatment. Among them, 14 received local treatment, while 59 did not. The methods included NHT (enzalutamide, abiraterone, apalutamine), Chemotherapy (additional platinum-based chemotherapy or docetaxel only), other therapies (inhibitors tyrosine...
<p>Concordance of genomic alterations between proggressive tumor tissue and matched ctDNA from patients with AVPC. <b>A,</b> Concordance in SMs CNVs. Data are shown for 63 patients. <b>B,</b> Rose diagram concordance + CNVs, only or CNVs only. <b>C,</b> Proportions high positive concordance, low negative concordance. <b>D,</b> Association clinical characteristics, including the ctDNA%, AVPC criteria, progressive status, PSA ≥ 10 ng/mL at...